Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00623597
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Phase 1
Completed
- Conditions
- Hematologic Neoplasms
- Interventions
- Drug: RO5045337
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 116
- Registration Number
- NCT00623870
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT00623805
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: RO4917838Drug: PlaceboDrug: Standard antipsychotic therapy
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 323
- Registration Number
- NCT00616798
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: enfuvirtide [Fuzeon]Drug: Optimized background ARV therapy
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00615134
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]Drug: Entecavir
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 219
- Registration Number
- NCT00614471
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT00607048
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Phase 2
Completed
- Conditions
- Liver Cancer
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT00605722
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Drug: Darbepoetin alfa
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT00605345
A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: Epoetin alfaDrug: methoxy polyethylene glycol-epoetin beta
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 101
- Registration Number
- NCT00605293
© Copyright 2025. All Rights Reserved by MedPath